United Therapeutics: FDA Acknowledges Acceptance of Tyvaso DPI Application
January 18 2022 - 7:45AM
Dow Jones News
By Will Feuer
United Therapeutics Corp. said the U.S. Food and Drug
Administration has acknowledged acceptance of its new drug
application for its Tyvaso DPI lung-disease treatment.
The Silver Spring, Md., biotechnology company said the FDA has
accepted the application for review as a class 1 response with a
user fee goal date in February.
The company is seeking approval of the drug for the treatment of
pulmonary arterial hypertension and pulmonary hypertension
associated with interstitial lung disease, to improve exercise
capacity.
The FDA in October had turned away the application, citing a
single deficiency related to an open inspection issue at a
third-party testing plant.
United Therapeutics said at the time that it believed the issue
would be resolved quickly, paving the way for FDA approval of
Tyvaso DPI by the summer of 2022. In December, it refiled its
application.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
January 18, 2022 07:30 ET (12:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Mar 2024 to Apr 2024
United Therapeutics (NASDAQ:UTHR)
Historical Stock Chart
From Apr 2023 to Apr 2024